Add BrightSurf on Google Email

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 2, 2026

Researchers have developed new CXCR4-targeting radiolabeled peptides for cancer imaging and therapy, producing clear tumor images and extending survival in preclinical testing studies. Additionally, PET scans are being used to predict prostate cancer outcomes, identify primary aldosteronism, and guide treatment decisions.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateFeb 1, 2026

Insights from brain’s waste-flushing system may improve diagnosis of idiopathic intracranial hypertension

Researchers used MRI analysis to measure glymphatic system activity, finding changes related to IIH stage and pressure levels. The findings suggest a noninvasive test could diagnose IIH more reliably, improving treatment options for patients with symptoms including headaches and vision loss.

SourceMass General Brigham·JournalJournal of Neuro-Ophthalmology·TypeExperimental study·DateJan 27, 2026

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 23, 2026

This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 23, 2026

Bringing optical color to ultrasound

Scientists have developed a new technique that combines rotational ultrasound tomography (RUST) with photoacoustic tomography (PAT) to create 3D color images of soft tissues and blood vessel function. This method has the potential to enhance breast tumor imaging, monitor nerve damage caused by diabetes, and brain imaging.

SourceCalifornia Institute of Technology·JournalNature Biomedical Engineering·DateJan 23, 2026

The Journal of Nuclear Medicine ahead-of-print tip sheet: January 16, 2026

Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 16, 2026

Novel theranostic model shows curative potential for gastric and pancreatic tumors

A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 15, 2026

New PET imaging breakthrough expands possibilities

Researchers at Virginia Tech have developed a new method for attaching fluorine-18 to trifluoromethyl groups, enabling the tagging of previously inaccessible targets in PET scans. This breakthrough expands the range of molecules that can be imaged, potentially leading to earlier diagnoses and more targeted treatments for diseases.

SourceVirginia Tech·JournalScience·DateDec 18, 2025

New Raman imaging system detects subtle tumor signals

Researchers developed a new compact Raman imaging system that can differentiate between tumor and normal tissue, offering a promising route to earlier cancer detection. The system uses special SERS nanoparticles to detect faint signals from tumor markers, highlighting spots likely to contain tumor tissue.

SourceOptica·JournalOptica·DateDec 18, 2025

ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification

Researchers developed multimodal models integrating imaging, clinical, and molecular data from TAILORx tissue biorepository for early-stage breast cancer. The models demonstrated enhanced prognostic performance compared to existing methods, highlighting their potential for personalized treatment decision-making.

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: December 5, 2025

Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateDec 5, 2025

Fullerenes for finer detailed MRI scans

Scientists have successfully used fullerenes as polarizing agents to improve MRI imaging capabilities, enabling clearer images with greater sensitivity. This breakthrough technique could lead to enhanced diagnostic capabilities and faster detection of diseases, potentially revolutionizing medical imaging.

SourceUniversity of Tokyo·JournalNature Communications·TypeExperimental study·DateDec 4, 2025

Clogged ‘drains’ in the brain a likely early-warning sign of Alzheimer’s disease, find NTU Singapore scientists

A study by NTU Singapore researchers found that enlarged perivascular spaces, or 'clogged drains', in the brain are a likely early-warning sign of Alzheimer's disease. The condition can be visually identified on routine MRI scans, complementing existing methods to detect Alzheimer's earlier.

SourceNanyang Technological University·JournalNeurology·TypeObservational study·DateNov 18, 2025

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 14, 2025

Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 14, 2025

Breakthrough MRI contrast agent design continues path to safer, more effective diagnostics

Scientists at the University of Birmingham have developed a new class of MRI contrast agents that are significantly more efficient and stable than current clinical agents. The novel metallo-coiled coil approach demonstrates a 30% increase in MRI relativity and unprecedented enhancement in chemical and biological stability.

SourceUniversity of Birmingham·JournalJournal of the American Chemical Society·DateNov 7, 2025

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 7, 2025

Researchers developed a detailed kidney model to study radiation distribution, highlighting uneven exposure across different nephron types. Tumor volume changes and PSMA PET imaging also showed promise for predicting outcomes in prostate cancer patients. New targeted therapies and imaging strategies aim to improve diagnosis and treatment.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 7, 2025

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 17, 2025

Recent studies published in The Journal of Nuclear Medicine explore the use of artificial intelligence to improve PSMA PET/CT scan interpretation, as well as its impact on treatment decisions for patients with recurrent prostate cancer. Brain metabolic changes and fibroblast activation protein (FAP) PET imaging also reveal new insights...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateOct 17, 2025

NUH and NUS launch new Molecular Imaging and Theranostics Centre to strengthen patient care and research

The new Molecular Imaging and Theranostics Centre at NUH and NUS Medicine enables faster, safer and more precise diagnoses, while researchers can observe real-time tracer movement throughout the body. This opens possibilities for validating next-generation diagnostics and therapies, advancing theranostics.

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 10, 2025

Studies have found that men with advanced prostate cancer can benefit from continuing PSMA therapy despite early PSA rise, while a new PET/CT scan may improve surgery decisions in pancreatic cancer. Molecular imaging advancements also hold promise for distinguishing aggressive kidney cancers and guiding treatment decisions.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateOct 10, 2025